184 related articles for article (PubMed ID: 31961236)
1. Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
Takase M; Kimura H; Kanahara N; Nakata Y; Iyo M
J Psychopharmacol; 2020 May; 34(5):540-547. PubMed ID: 31961236
[TBL] [Abstract][Full Text] [Related]
2. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
Oda Y; Kanahara N; Iyo M
Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-induced supersensitivity - A reappraisal.
Lugg W
Aust N Z J Psychiatry; 2022 May; 56(5):437-444. PubMed ID: 34144649
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic-evoked dopamine supersensitivity.
Servonnet A; Samaha AN
Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
[TBL] [Abstract][Full Text] [Related]
6. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
[TBL] [Abstract][Full Text] [Related]
7. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
Seeman P
CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
[TBL] [Abstract][Full Text] [Related]
8. Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.
Kanahara N; Kimura H; Oda Y; Ito F; Iyo M
Curr Neuropharmacol; 2021; 19(12):2214-2226. PubMed ID: 33550976
[TBL] [Abstract][Full Text] [Related]
9. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
10. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
11. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia.
Kanahara N; Yoshimura K; Nakamura M; Oda Y; Watanabe M; Iyo M
Int Clin Psychopharmacol; 2019 May; 34(3):124-130. PubMed ID: 30870237
[TBL] [Abstract][Full Text] [Related]
13. The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia.
Takase M; Kanahara N; Oda Y; Niitsu T; Watanabe H; Iyo M
Schizophr Res; 2017 Dec; 190():182-183. PubMed ID: 28285026
[No Abstract] [Full Text] [Related]
14. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time.
Samaha AN; Seeman P; Stewart J; Rajabi H; Kapur S
J Neurosci; 2007 Mar; 27(11):2979-86. PubMed ID: 17360921
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
Kanahara N; Takase M; Sasaki T; Honma M; Fujita Y; Tadokoro S; Suzuki H; Yamanaka H; Noda S; Yanahashi S; Saiga T; Komatsu N; Simoyama T; Iyo M
Int Clin Psychopharmacol; 2020 Nov; 35(6):338-344. PubMed ID: 32868522
[TBL] [Abstract][Full Text] [Related]
16. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.
Yin J; Barr AM; Ramos-Miguel A; Procyshyn RM
Curr Neuropharmacol; 2017; 15(1):174-183. PubMed ID: 27264948
[TBL] [Abstract][Full Text] [Related]
18. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
[TBL] [Abstract][Full Text] [Related]
19. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice.
Yamasaki F; Kanahara N; Nakata Y; Koyoshi S; Yanagisawa Y; Saito T; Oiwa T; Kogure M; Sasaki T; Yoshida T; Kimura H; Iyo M
J Psychopharmacol; 2023 Oct; 37(10):992-1002. PubMed ID: 37395368
[TBL] [Abstract][Full Text] [Related]
20. Are dopamine D2 receptors out of control in psychosis?
Seeman P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():146-52. PubMed ID: 23880595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]